Celltrion’s Steqeyma approved in CAN…targets Stelara mkt
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.01 05:05:58
가나다라
0
Approved in Canada following domestic approval in June and CHMP’s recommendation for EU approval
Company expands area to IL inhibitors after TNF-α inhibitors... Strengthens its autoimmune disease portfolio
On the 31st, Celltrion announced that it had received New Drug Application (NDS) approval for its Stelara biosimilar Steqeyma from Health Canada.
With the approval, Celltrion may now sell Steqeyma in Canada for plaque psoriasis, psoriatic arthritis, and Crohn's disease.
The Canadian approval supports the company’s plan to settle into the global ustekinumab market starting with North America, the largest pharmaceutical market.
According to IQVIA, the global ustekinumab market was valued at around USD 20.4 billion (KRW 26.52 trillion) last year, with the Canadian market recording USD 663 million (KRW 861.9 billion).
When including the U.S. market, th
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)